Related Experiment Video
Updated: Aug 10, 2026

Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
Hypoxia-inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas
Alexandra Giatromanolaki1, Efthimios Sivridis, Aliki Fiska
1Department of Pathology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece. targ@her.forthnet.gr
Abstract:
Hypoxia-inducible factors-1alpha (HIF-lalpha) and HIF-2alpha are important proteins initiating tumor cell responses to hypoxia. Specifically, the transcription of genes related to erythropoiesis, glycolysis, and angiogenesis depends on the rate of HIFalpha binding to DNA at the hypoxia response elements of target genes. In this study, the authors evaluated the immunohistochemical expression of HIF-2alpha in 62 infiltrating ductal carcinomas of the breast, not otherwise specified, in relation to estrogen and progesterone receptors, the MIB1 proliferation index, the vascular density, and the proteins c-erbB-2, bcl-2, and p53. Extensive and strong cytoplasmic and/or nuclear expression of HIF-2alpha was noted in 23 of the 64 (35.9%) cases, and this was associated with increased vascular density (P=0.0002), increased c-erbB-2 membrane expression (P=0.02), and secondary deposits to multiple axillary lymph nodes (>3). In multivariate analysis, HIF-2alpha and T stage were the only variables related to extensive nodal metastasis. The authors conclude that HIF-2alpha overexpression, a common event in infiltrating ductal carcinomas of the breast, is related to high metastatic potential via increased angiogenic and c-erbB-2 activity.
More Related Videos
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mechanism of Angiogenesis
PI3K/mTOR/AKT Signaling Pathway
The Tumor Microenvironment
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

